Research Progress of Fibroblast Growth Factor 21 in Fibrotic Diseases.

Fibrosis is a common pathological outcome of chronic injuries, characterized by excessive deposition of extracellular matrix components in organs, as seen in most chronic inflammatory diseases. At present, there is an increasing tendency of the morbidity and mortality of diseases caused by fibrosis, but the treatment measures for fibrosis are still limited. Fibroblast growth factor 21 (FGF21) belongs to the FGF19 subfamily, which also has the name endocrine FGFs because of their endocrine manner. In recent years, it has been found that plasma FGF21 level is significantly correlated with fibrosis progression. Furthermore, there is evidence that FGF21 has a pronounced antifibrotic effect in a variety of fibrotic diseases. This review summarizes the biological effects of FGF21 and discusses what is currently known about this factor and fibrosis disease, highlighting emerging insights that warrant further research. Copyright © 2022 Min-Qi Jia et al.

Citation

Min-Qi Jia, Cha-Xiang Guan, Jia-Hao Tao, Yong Zhou. Research Progress of Fibroblast Growth Factor 21 in Fibrotic Diseases. Oxidative medicine and cellular longevity. 2022;2022:5042762

Mesh Tags

Substances

PMID: 35677107

search → result